Summary
PROJECT SUMMARY/ABSTRACT Chimeric Antigen Receptors (CAR) are engineered receptors that direct the killing activity of T cells to targets of interest and have had dramatic results in the treatment of B cell leukemia. However, the application of this technology to lung tumor remains challenging in part due to inhibitory tumor microenvironments (TME). An immunosuppressive TME is seen even at the earliest stages of human lung cancer. These tumors are infiltrated with immunosuppressive cells including macrophages and T regulatory cells, and have a reduction in effector T cells. Clinical trials usi
